Clinical Trial Update: Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR) [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial is evaluating anti-VEGF therapy for high-risk diabetic retinopathy using Ranibizumab, with the current status undisclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Diabetic Retinopathy, Ranibizumab | Phase 3 | Status: UNKNOWN